Abstract

Stretch-shortening cycles (SSCs) refer to the muscle action when an active muscle stretch is immediately followed by active muscle shortening. This combination of eccentric and concentric contractions is the most important type of daily muscle action and plays a significant role in natural locomotion such as walking, running or jumping. SSCs are used in human and animal movements especially when a high movement speed or economy is required. A key feature of SSCs is the increase in muscular force and work during the concentric phase of a SSC by more than 50% compared with concentric muscle actions without prior stretch (SSC-effect). This improved muscle capability is related to various mechanisms, including pre-activation, stretch-reflex responses and elastic recoil from serial elastic tissues. Moreover, it is assumed that a significant contribution to enhanced muscle capability lies in the sarcomeres itself. Thus, we investigated the force output and work produced by single skinned fibers of rat soleus muscles during and after ramp contractions at a constant velocity. Shortening, lengthening, and SSCs were performed under physiological boundary conditions with 85% of the maximum shortening velocity and stretch-shortening magnitudes of 18% of the optimum muscle length. The different contributions of cross-bridge (XB) and non-cross-bridge (non-XB) structures to the total muscle force were identified by using Blebbistatin. The experiments revealed three main results: (i) partial detachment of XBs during the eccentric phase of a SSC, (ii) significantly enhanced forces and mechanical work during the concentric phase of SSCs compared with shortening contractions with and without XB-inhibition, and (iii) no residual force depression after SSCs. The results obtained by administering Blebbistatin propose a titin-actin interaction that depends on XB-binding or active XB-based force production. The findings of this study further suggest that enhanced forces generated during the active lengthening phase of SSCs persist during the subsequent shortening phase, thereby contributing to enhanced work. Accordingly, our data support the hypothesis that sarcomeric mechanisms related to residual force enhancement also contribute to the SSC-effect. The preload of the titin molecule, acting as molecular spring, might be part of that mechanism by increasing the mechanical efficiency of work during physiological SSCs.

Highlights

  • Residual force depression following active muscle shortening and residual force enhancement following active muscle stretch (Abbott and Aubert, 1952) are fundamentally accepted mechanical properties of skeletal muscle (Rassier, 2017)

  • Despite clear evidence concerning increased SSCeffects in various experimental human and animal studies on different structural levels, the underlying mechanisms remain controversial. This dispute is because none of the currently accepted mechanisms (such as preactivation, Abbreviations: adenosine triphosphate disodium salt hydrate (ATP), adenosine 5 triphosphate disodium salt hydrate; BDM, 2,3butanedione monoxime; Ca2+, calcium; CK, creatine phosphokinase; CP, creatine phosphate; E-64, trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane; EGTA, ethylene glycol-bis(2-aminoethylether)-N,N,N,N -tetraacetic acid; F/F0, maximum isometric muscle force; GLH, glutathione; HDTA, 1,6-diaminohexaneN,N,N,N -tetraacetic acid; h, height; IMID, imidazole; KOH, potassium hydroxide; KP, potassium propionate; L/L0, optimum muscle fiber length associated with F/F0; non-XB, non-cross-bridge; PMSF, phenylmethanesulfonyl fluoride; rFD, residual force depression; rFE, residual force enhancement; shortening was preceded by stretching (SSC), stretch-shortening cycle; TES, N-[tris(hydroxymethyl)methyl]-2aminoethanesulfonic acid; v/v, volume/volume; vmax, maximal shortening velocity; w, width; w/w, weight/volume; XB, cross-bridge

  • The findings of this study reveal the following: (I) The SSC-effect is present at the single skinned muscle fiber level

Read more

Summary

Introduction

Residual force depression (rFD) following active muscle shortening and residual force enhancement (rFE) following active muscle stretch (Abbott and Aubert, 1952) are fundamentally accepted mechanical properties of skeletal muscle (Rassier, 2017). Despite clear evidence concerning increased SSCeffects in various experimental human and animal studies on different structural levels (in vitro, in situ, in vivo), the underlying mechanisms remain controversial This dispute is because none of the currently accepted mechanisms (such as preactivation, Abbreviations: ATP, adenosine 5 triphosphate disodium salt hydrate; BDM, 2,3butanedione monoxime; Ca2+, calcium; CK, creatine phosphokinase; CP, creatine phosphate; E-64, trans-epoxysuccinyl-L-leucylamido(4-guanidino)butane; EGTA, ethylene glycol-bis(2-aminoethylether)-N,N,N ,N -tetraacetic acid; F/F0, maximum isometric muscle force; GLH, glutathione; HDTA, 1,6-diaminohexaneN,N,N ,N -tetraacetic acid; h, height; IMID, imidazole; KOH, potassium hydroxide; KP, potassium propionate; L/L0, optimum muscle fiber length associated with F/F0; non-XB, non-cross-bridge; PMSF, phenylmethanesulfonyl fluoride; rFD, residual force depression; rFE, residual force enhancement; SSC, stretch-shortening cycle; TES, N-[tris(hydroxymethyl)methyl]-2aminoethanesulfonic acid; v/v, volume/volume; vmax, maximal shortening velocity; w, width; w/w, weight/volume; XB, cross-bridge

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.